Lianyong Chen
Founder and Managing Partner @ Frontline BioVentures
Lianyong Chen is a Series A investor at Frontline BioVentures focused on Biotechnology and Biopharma. Dr. Chen is Founder and Managing Partner of Frontline BioVentures. Leon has over 19 years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor. He is a member of the Expert Review Panel for the Chinese Central Government HR’s 1000 Talent Plan,and an adviser to BioBAY of Suzhou Industry Park. As a venture capital investor, his current and past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Director of Board, Acting CFO), Cathay Industrial Biotechnology (Director of Board), Hile Biopharma (Director of Board), Hua Medicine (Shanghai) (Director of Board), Innovent Biologics Ltd (Chairman), Adagene (Director of Board) and MDDF (Director of Board). As a management consultant, his past affiliations include McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area). As a Ph.D. scientist, he worked with Schering Plough (New Jersey), and is a key member of the discovery team of Zytia / Vytorin - a multi-billion drug. Mr. Chen was a Post-Doc at MIT, Ph.D. (with top honor) from the University of Louvain, Louvain-La-Neuve, B.S. from Peking University. Leon holds 6 issued US Patents, and is co-author of the 14th and 15th Ernst & Young Biotechnology Annual Report.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Lianyong Chen invests in
Stages Lianyong Chen invests in
Countries Lianyong Chen invests in
Investment Focus
Industry
- Biotechnology 4 (80%)
- Biopharma 2 (40%)
- Pharmaceutical 2 (40%)
- Medical 1 (20%)
- Wellness 1 (20%)
Stage
- Series A 2 (40%)
- Series B 2 (40%)
- Series C 1 (20%)
Country
- China 2 (40%)
- United States 2 (40%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ignis Therapeutics
|
Ignis Therapeutics is a innovative therapies in the field of central nervous system. | $180M / Series A / Nov 11, 2021 | |
Ultivue
|
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and willeventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts. | $22M / Series C / Jun 14, 2019 | |
Viela Bio
|
Viela Bio is a clinical-stage biotechnology company pioneering and advancing treatments for severe inflammation and autoimmune diseases. The Company’s portfolio selectively targets shared critical pathways that are the root cause of disease. Led by a team of global leaders in inflammation and autoimmunity, Viela Bio strives to be a fully integratedbiotechnology company, helping millions of patients worldwide. Viela Bio is located in Gaithersburg, Maryland. | $282.3M / Series A / Feb 28, 2018 | |
|
Ultivue
|
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and willeventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts. | Series B / Jan 23, 2018 | |
AnchorDx
|
Guangzhou Baseline Medical is committed to building a world-class clinical application of high-throughput sequencing and R & D platform to become the leading global provider of precision medical solutions. The company's core team has more than 20 years of senior industry experience, involved in cancer genomics, genetics and bioinformaticsand other fields.Based on its core technical advantages, the Company aims at precision medicine, establishes a cooperative relationship with middle and downstream enterprises in the industry, and forms a complete industrial chain from academic research to clinical product transformation. It has also established close cooperation with many large-scale third-party inspection agencies including Illumina, Well-known domestic and foreign hospitals and research institutes to establish cooperative relations, the development of a series of independent intellectual property rights and international competitiveness of clinical testing products for patients, doctors and medical institutions to provide accurate, convenient and comprehensive services. | $28M / Series B / Nov 07, 2017 |
Co-Investors
About Frontline BioVentures
###Frontline BioVentures merged with WuXi Healthcare Ventures to form 6 Dimensions Capital###Frontline BioVentures is a premier China-based venture capital firm specialize in the investment of innovative life science companiesWe focus on business within strategic life science and technology areas promoted by the Chinese government.Currentlywe manage two funds, a RMB denominated fund and a parallel USD fund, which offers structural flexibilities to best serve the needs of portfolio companies.
Frontline BioVentures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Lianyong Chen
Founder and Managing Partner
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Lianyong Chen invest in?
Lianyong Chen invests primarily in Biotechnology, Biopharma and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Lianyong Chen last invest?
The most recent investment recorded for Lianyong Chen closed in Nov 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
